The goal of this clinical trial is to evaluate whether daily supplementation with cold-pressed pecan nut oil can reduce inflammation in adults with overweight. The main questions it aims to answer are:
Does pecan nut oil supplementation reduce inflammatory biomarkers, including C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α)? Does pecan nut oil supplementation improve biochemical parameters such as fasting blood glucose and lipid profile? Researchers will compare an experimental group receiving pecan nut oil to a control group with no intervention to determine its effect on inflammation and metabolic parameters.
Participants will:
Consume 30 g/day of cold-pressed pecan nut oil under fasting conditions for 8 weeks (experimental group) Maintain their usual diet and physical activity throughout the study Attend two evaluation visits (baseline and Day 60) for blood sample collection and anthropometric measurements Provide dietary information using a 24-hour dietary recall
Adults aged 18 to 65 years
Body mass index (BMI) ≥25 and <30 kg/m² (overweight)
Willingness to participate and provide written informed consent
Ability to comply with study procedures and attend scheduled visits
Diagnosis of chronic diseases such as diabetes mellitus, cardiovascular disease, liver disease, renal disease, or autoimmune disorders
Use of anti-inflammatory medications, lipid-lowering drugs, or dietary supplements within the last 3 months
Smoking or excessive alcohol consumption
Pregnancy or lactation
Universidad Autonoma de Nuevo Leon
Lead sponsor
Hospital Universitario Dr. Jose E. Gonzalez
Collaborator
Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco
Collaborator